US Patent 8,623,826: Scope, Claim Analysis, Expiration Risk, and Netupitant-Palonosetron Patent Landscape

US Patent 8,623,826 protects treatment regimens using netupitant and palonosetron, with optional reduced-dose dexamethasone, for chemotherapy-induced nausea and vomiting. Its strongest commercial claims are directed to the oral 300 mg netupitant/0.5 mg palonosetron regimen marketed as Akynzeo, particularly when paired with the claimed dexamethasone schedule. The patent is a method-of-treatment patent, not a composition patent, and does not independently block every product containing netupitant or palonosetron.

The principal infringement risks concern products that administer both active ingredients before moderately or highly emetogenic chemotherapy and use the claimed one-dose, five-day treatment concept. The most commercially important claims are 13, 14, 21, and 23. Claims 1 through 18 add narrower dexamethasone, dose, pharmacodynamic, route, and indication limitations. Claims 19 through 25 create a broader combination-treatment platform that does not always require dexamethasone.

What does US Patent 8,623,826 cover?

US 8,623,826 is directed to methods for treating nausea and vomiting by combining:

Netupitant, an NK1 receptor antagonist;
Palonosetron, a 5-HT3 receptor antagonist; and
In several claims, reduced-dose dexamethasone.

The claimed regimen is designed to cover the acute and delayed phases of CINV following moderately or highly emetogenic chemotherapy. The patent claims both the pharmacological combination and the dosing schedule.

The patent does not claim a new molecular entity. Netupitant and palonosetron are separately defined active pharmaceutical ingredients, and the claims are framed around their use together in a particular clinical regimen.

The patent’s commercial relevance derives from the relationship between the claims and Akynzeo, an oral fixed-dose combination of netupitant and palonosetron approved by the FDA for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including highly emetogenic chemotherapy and moderately emetogenic chemotherapy.[1]

What are the independent claims of US 8,623,826?

The central independent claims are claims 1 and 19.

Claim 1: five-day regimen with reduced-dose dexamethasone

Claim 1 requires all of the following:

Administration of netupitant or a pharmaceutically acceptable salt on day one.
Netupitant must enter systemic circulation, cross the blood-brain barrier, and occupy at least 70% of NK1 receptors in the striatum 72 hours after administration.
Administration of palonosetron on day one.
Administration of a first dexamethasone dose on day one.
The day-one dexamethasone dose must be ineffective against CINV when used alone.
The dexamethasone dose must be effective in combination with netupitant.
The first dexamethasone dose must equal 50% to 70% of the minimum effective dose of dexamethasone when used alone.
The combination must treat both nausea and vomiting during days one through five.
The combination must be more effective than palonosetron and dexamethasone without netupitant.

Claim 1 is therefore narrower than a simple “netupitant plus palonosetron” claim. It includes a pharmacodynamic receptor-occupancy limitation and a comparative therapeutic-effect limitation.

Claim 19: broader netupitant-palonosetron combination

Claim 19 covers treating CINV during the acute or delayed phase by administering netupitant and palonosetron before moderately or highly emetogenic chemotherapy.

Unlike claim 1, claim 19 does not require:

Dexamethasone;
A five-day treatment period;
A particular NK1 receptor occupancy level;
A specific comparative result against palonosetron and dexamethasone; or
Administration of a second dexamethasone dose.

Claim 19 is the broadest commercially important claim because it can potentially read on the administration of the netupitant-palonosetron combination alone, subject to the chemotherapy, timing, and indication limitations.

Which dependent claims matter most commercially?

Claim	Main limitation	Commercial significance
2	Dexamethasone on days two, three, and four at 40% to 60% of the standalone minimum effective dose	Covers the full reduced-dose continuation regimen
3	At least 80% NK1 receptor occupancy at 72 hours	Narrow pharmacodynamic limitation
4	Only one netupitant dose during five days	Relevant to single-dose products
5	One oral netupitant dose during five days	Closely aligned with oral Akynzeo use
6	Netupitant dose of approximately 200 to 400 mg	Broad dose range around the commercial dose
7	Approximately 300 mg netupitant free base	Directly targets the Akynzeo netupitant strength
8	Standalone dexamethasone minimum effective dose of approximately 16 to 20 mg	Defines the reference dose for the reduced-dose limitation
9	One palonosetron dose during five days	Aligns with single-dose palonosetron use
10	Palonosetron dose of approximately 0.25 to 0.75 mg	Covers the commercial 0.5 mg free-base dose
11	Approximately 0.56 mg palonosetron hydrochloride	Directly corresponds to 0.5 mg palonosetron free base
12	Oral palonosetron	Targets oral fixed-dose products
13	300 mg netupitant, 0.56 mg palonosetron hydrochloride, and 12 mg dexamethasone on day one	Strong product-regimen alignment
14	Claim 13 plus 8 mg dexamethasone on days two, three, and four	Directly covers the four-day dexamethasone schedule
15	CINV, RINV, or PONV	Expands the disease-use language
16	Moderately or highly emetogenic chemotherapy	Core clinical indication
17	Chemotherapy administered one to two hours after netupitant	Adds timing specificity
18	Acute or delayed phases of moderate or highly emetogenic chemotherapy	Covers the principal CINV treatment windows
20	Oral netupitant and palonosetron in defined dose ranges	Broad oral combination claim
21	300 mg netupitant plus 0.56 mg palonosetron hydrochloride	Directly targets the fixed-dose combination
22	Subtherapeutic dexamethasone for highly emetogenic chemotherapy	Adds a dexamethasone condition
23	12 mg dexamethasone on day one and 8 mg on days two through four	Directly covers the standard high-risk regimen
24	Synergistic antagonism of NK1 activity	Functional combination limitation
25	Same synergy limitation applied to claim 19	Narrows the broad combination claim

Claims 13, 14, 21, and 23 have the closest relationship to the marketed clinical regimen. Claims 7 and 11 identify the active-ingredient amounts corresponding to the commercial product. Claim 19 has greater breadth but may present more substantial proof issues because infringement requires establishing the claimed clinical context and administration sequence.

How does the claim scope compare with Akynzeo?

Akynzeo contains netupitant and palonosetron in a fixed-dose oral capsule. The US prescribing information identifies the product as containing 300 mg of netupitant and 0.5 mg of palonosetron, with palonosetron present as approximately 0.56 mg of palonosetron hydrochloride.[1]

The product therefore aligns closely with the following limitations:

Claim 5: one oral netupitant dose;
Claim 7: approximately 300 mg netupitant;
Claim 11: approximately 0.56 mg palonosetron hydrochloride;
Claim 12: oral palonosetron;
Claim 16: moderately or highly emetogenic chemotherapy;
Claim 19: netupitant and palonosetron before chemotherapy;
Claim 21: the commercial netupitant-palonosetron dose.

The product alone does not necessarily satisfy claims requiring dexamethasone. Those claims depend on the physician’s or protocol’s accompanying dexamethasone administration. A product label that recommends dexamethasone could increase inducement or contributory-infringement exposure, depending on the accused conduct and applicable case law.

What are the principal claim-construction issues?

NK1 receptor occupancy

Claims 1 and 3 require netupitant to occupy at least 70% or 80% of NK1 receptors in the striatum 72 hours after administration. This is a pharmacodynamic limitation, not merely a dose limitation.

A challenger could argue that the claim requires proof of actual receptor occupancy in the treated patient or that the limitation is not sufficiently measurable from routine prescribing information. The patent owner could argue that the limitation describes a pharmacological property associated with the claimed netupitant dose and regimen.

This limitation is absent from claim 19 and its principal dose-range dependent claims. That makes claims 19 through 21 more important in a generic or follow-on-product dispute.

Reduced-dose dexamethasone

Claims 1, 2, 8, 13, 14, 22, and 23 depend on the concept that dexamethasone is ineffective alone at the claimed dose but effective when combined with netupitant and palonosetron.

The claim uses relative efficacy concepts rather than only fixed milligram amounts. Claims 13 and 14 reduce some uncertainty by specifying 12 mg on day one and, in claim 14, 8 mg on days two through four. Claims 8 and 23 are more dependent on how “minimum effective dose” and “sub-therapeutic dose” are construed.

Synergy

Claims 24 and 25 require synergistic effectiveness. Synergy is generally more demanding than additive activity. The patent owner would need to establish that the interaction between the agents exceeds the expected effect of the individual agents or their baseline combination.

Claim 24 also refers to netupitant and palonosetron being synergistically effective to antagonize NK1 activity. Netupitant is the NK1 antagonist, while palonosetron is primarily a 5-HT3 antagonist. That language creates a potential construction and validity issue if interpreted as requiring palonosetron itself to antagonize NK1 receptors rather than contribute to a broader antiemetic effect.

How strong is the patent estate around netupitant and palonosetron?

The patent estate has several distinct layers:

Estate layer	Subject matter	Relevance
Active-ingredient patents	Netupitant molecule, salts, and related compounds	May block manufacture or sale of netupitant independently of the combination
Combination patents	Netupitant plus palonosetron	Core Akynzeo product protection
Method-of-treatment patents	CINV prevention, acute and delayed phases, chemotherapy timing	Relevant to clinical use and inducement
Formulation patents	Oral fixed-dose capsule, excipients, release and stability characteristics	Relevant to product design and ANDA similarity
Process patents	Manufacture, crystallization, purification, and salt forms	Can create supply-chain barriers
Regulatory exclusivity	FDA new-drug or clinical-investigation exclusivity	Operates separately from patent rights

US 8,623,826 is principally in the method-of-treatment layer. It does not by itself establish protection for every formulation, manufacturing process, salt, polymorph, or dosage form containing the two active ingredients.

What is the FDA and Orange Book significance?

Akynzeo was approved by the FDA in October 2014 under NDA 208109.[2] The product is a fixed-dose combination rather than a biologic, so biosimilar pathways do not apply. A competing product would ordinarily proceed through an ANDA if it qualifies as therapeutically equivalent to the listed drug, or through a 505(b)(2) application if it relies on the listed drug but differs materially in formulation, dosage form, or clinical use.

The Orange Book analysis should distinguish:

Listed patents for the approved drug;
Patent-use codes associated with each listed method-of-use patent;
Patent expiration dates after patent-term adjustment;
Any pediatric exclusivity;
NDA exclusivity;
Paragraph IV certifications submitted by ANDA applicants.

A Paragraph IV certification would assert that a listed patent is invalid, unenforceable, or not infringed. If the NDA holder receives timely notice and files suit within the statutory period, the filing can trigger a 30-month stay of final ANDA approval under the Hatch-Waxman framework.[3]

The claims supplied here do not establish the current Orange Book listing status, patent-term adjustment, or any live Paragraph IV litigation. Those facts must be taken from the current FDA Orange Book entry and USPTO patent record rather than inferred from the claim language.

When does US 8,623,826 lose exclusivity?

The patent’s enforceable expiry date cannot be determined from the claims alone. It depends on the patent family’s earliest effective nonprovisional filing date, patent-term adjustment, terminal disclaimers, and any patent-term extension.

The relevant exclusivity timeline is:

Event	Date or status
US 8,623,826 issued	January 7, 2014
FDA approval of Akynzeo	October 10, 2014
Patent term	Generally 20 years from the applicable earliest nonprovisional filing date
Patent-term adjustment	Must be confirmed in the USPTO record
FDA exclusivity	Separate from patent term and determined from the NDA record
Generic entry	Dependent on patent certifications, litigation, settlement, and FDA approval

The issue date is not the patent-expiration date. A patent issued in 2014 can expire before or after 2030 depending on its priority and filing history.

What generic entry risks exist?

A generic or 505(b)(2) competitor could pursue several design-around strategies:

Use netupitant and palonosetron but avoid the claimed dexamethasone regimen.
Use a different dose or administration schedule.
Avoid the claimed one-dose, five-day treatment pattern.
Develop a nonoral formulation.
Rely on a different NK1 antagonist, such as aprepitant or fosaprepitant.
Market the product with labeling that omits the patented use, subject to inducement and label-scrubbing limits.
Challenge the patent through Paragraph IV certification.

The broadest practical risk remains claim 19 and its dose-specific dependents. A competitor that sells the same two-drug combination for the same chemotherapy setting cannot assume that avoiding dexamethasone avoids infringement.

Claims 1 through 18 are more vulnerable to design-around because they require multiple factual conditions. Claims 13, 14, 21, and 23 are narrower but commercially more direct because they specify the doses used in practice.

How does this patent compare with competing antiemetic products?

Product or regimen	Principal mechanism	Relationship to US 8,623,826
Akynzeo	Netupitant plus palonosetron	Directly aligned with claims 19 to 21
Emend	Aprepitant	Different NK1 molecule; generally outside the literal netupitant limitations
Fosaprepitant	Injectable prodrug of aprepitant	Different active ingredient and route
Aloxi	Palonosetron alone	Does not meet the netupitant requirement
Varubi	Rolapitant	Different NK1 antagonist
Generic palonosetron	5-HT3 antagonist alone	Avoids the netupitant limitations
Fixed-dose netupitant-palonosetron competitor	Same two active ingredients	Highest direct claim risk

The patent creates less risk for competing NK1 antagonists than for a direct netupitant-palonosetron substitute. Its commercial impact is therefore concentrated in the fixed-dose combination market.

Does biosimilar risk apply?

No. Netupitant and palonosetron are small-molecule drugs, and Akynzeo is not a biologic licensed under the Public Health Service Act. Biosimilar approval procedures do not apply. Competition would arise through an ANDA, a 505(b)(2) application, or a direct new-drug application, depending on the proposed product and regulatory strategy.

What is the litigation and settlement exposure?

A Paragraph IV challenge could target:

Written description and enablement of the receptor-occupancy limitation;
Definiteness of “minimum effective dose” and “subtherapeutic dose”;
Proof of synergy;
Infringement of treatment claims based on the proposed label;
Obviousness over prior combinations of NK1 and 5-HT3 antagonists;
Obviousness of the reduced-dose dexamethasone regimen;
Patent-term and Orange Book listing issues.

The strongest validity arguments would likely focus on the functional and comparative limitations. The strongest infringement arguments would likely focus on a proposed label that expressly recommends the same netupitant, palonosetron, chemotherapy, and dexamethasone regimen described in claims 13, 14, 21, and 23.

Key Takeaways

US 8,623,826 is a method-of-treatment patent covering netupitant-palonosetron antiemetic regimens.
Claim 19 is the broadest core combination claim because it does not require dexamethasone.
Claims 13, 14, 21, and 23 most closely track the commercial Akynzeo regimen.
Claims 1 and 3 add demanding NK1 receptor-occupancy limitations.
Claims 1, 2, 8, 22, and 23 depend on reduced or subtherapeutic dexamethasone concepts.
The patent does not itself establish composition, formulation, manufacturing, or salt protection.
Biosimilar competition is irrelevant because Akynzeo is a small-molecule product.
Generic risk is highest for a product containing both netupitant and palonosetron and labeled for CINV prevention before moderately or highly emetogenic chemotherapy.
The enforceable expiry date requires review of the USPTO patent-term record and any Orange Book patent-term adjustment.
A current freedom-to-operate analysis must review the entire Akynzeo patent family, not US 8,623,826 alone.

FAQs

Is US 8,623,826 a composition patent?

No. It is principally a method-of-treatment patent. It claims administration of netupitant, palonosetron, and in some claims dexamethasone for nausea and vomiting.

Does using palonosetron alone infringe US 8,623,826?

Generally, no literal infringement exists without the claimed netupitant administration. Claims 1 and 19 both require netupitant or an acceptable salt.

Does a generic need to use dexamethasone to infringe?

Not necessarily. Claim 19 and its principal dependent claims cover netupitant plus palonosetron without requiring dexamethasone. Dexamethasone is required by other claims.

Can a competitor avoid the patent by using aprepitant instead of netupitant?

Aprepitant is a different active ingredient. A product using aprepitant instead of netupitant would generally avoid the literal netupitant limitations, although other patents could apply.

Is the 300 mg netupitant and 0.5 mg palonosetron dose specifically protected?

Yes, that dose combination is expressly recited in claims 7, 11, 13, 14, and 21, subject to the additional limitations of each claim.

References

U.S. Food and Drug Administration. (2023). Akynzeo (netupitant and palonosetron) prescribing information.
U.S. Food and Drug Administration. (2014). FDA approves Akynzeo for prevention of chemotherapy-induced nausea and vomiting.
U.S. Code, 21 U.S.C. § 355(j). (2024). Abbreviated applications and patent certifications.
U.S. Patent No. 8,623,826. (2014). Methods of treating nausea and vomiting. U.S. Patent and Trademark Office.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Helsinn Hlthcare	AKYNZEO	netupitant; palonosetron hydrochloride	CAPSULE;ORAL	205718-001	Oct 10, 2014		RX	Yes	Yes	8,623,826	⤷ Start Trial				USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	3083	⤷ Start Trial
Australia	2010320598	⤷ Start Trial
Brazil	112012011485	⤷ Start Trial
Canada	2778301	⤷ Start Trial
Chile	2012001276	⤷ Start Trial
China	102655864	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,623,826

Which drugs does patent 8,623,826 protect, and when does it expire?

Summary for Patent: 8,623,826